On 24 April 2019, orphan designation (EU/3/19/2157) was granted by the European Commission to Dipharma B.V., the Netherlands, for sodium benzoate, sodium phenylacetate for the treatment of ornithine transcarbamylase deficiency.
|Disease / condition||
Treatment of ornithine transcarbamylase deficiency
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: